Highlights on medical treatment of uterine fibroids

S Angioni, MN D'Alterio… - Current Pharmaceutical …, 2021 - ingentaconnect.com
Uterine fibroids (leiomyomas or myomas) are the most frequent benign tumors in women.
Heavy menstrual bleeding with resultant anemia, dysmenorrhea, chronic pelvic pain …

Sex steroid receptors in polycystic ovary syndrome and endometriosis: insights from laboratory studies to clinical trials

F Abdul Hamid, MA Abu, AK Abdul Karim, MF Ahmad… - Biomedicines, 2022 - mdpi.com
Polycystic ovary syndrome (PCOS) and endometriosis are reproductive disorders that may
cause infertility. The pathology of both diseases has been suggested to be associated with …

90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies

HOD Critchley, RR Chodankar - Journal of molecular …, 2020 - jme.bioscientifica.com
Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition affecting
one in four women of reproductive age. Current treatments (conservative, medical and …

Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women

B Schütt, MH Schultze‐Mosgau… - The Journal of …, 2018 - Wiley Online Library
This randomized, double‐blind, parallel‐group study in healthy young women investigated
the effect of treatment with vilaprisan (0.5, 1, 2, or 4 mg/day for 12 weeks) on ovarian function …

CYP3A4‐mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1‐mediated effects on bilirubin glucuronidation in humans

N Chattopadhyay, T Kanacher… - British Journal of …, 2018 - Wiley Online Library
Aims The primary aim of the present study was to quantify the effects of rifampicin, a strong
cytochrome P450 (CYP) 3A4 inducer, on the pharmacokinetics of the new selective …

Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug–drug interaction potential

MH Schultze-Mosgau, J Höchel, O Prien… - Clinical …, 2018 - Springer
Background and objectives In-vitro data suggest that clearance of vilaprisan is mediated by
cytochrome P450 3A4 (oxidation) and aldoketoreductases (reduction). To fully understand …

Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy–2 case studies

M Ciebiera, B Męczekalski, K Łukaszuk… - Gynecological …, 2019 - Taylor & Francis
This is a preliminary report of the first cases of successful simultaneous use of ulipristal
acetate (UPA) and vitamin D3 in uterine fibroid (UF) oral treatment in humans. We present …

The latest advances in the pharmacological management of endometriosis

G Hartner, H Husslein, L Kuessel… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Endometriosis is a benign disease, characterized by a wide range of symptoms
and different degrees of severity, which is why therapy should be individually adapted to the …

Vilaprisan for treating uterine fibroids

GB Melis, M Neri, B Piras, AM Paoletti… - Expert opinion on …, 2018 - Taylor & Francis
Introduction: The medical strategy to antagonize myoma size and related-symptoms is to
reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH …

[HTML][HTML] Variation of outcome reporting in studies of interventions for heavy menstrual bleeding: a systematic review

NAM Cooper, R Papadantonaki, S Yorke… - Facts, Views & Vision …, 2022 - ncbi.nlm.nih.gov
Background Heavy menstrual bleeding (HMB) detrimentally effects women. It is important to
be able to compare treatments and synthesise data to understand which interventions are …